These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 8306591

  • 1. Different acute and chronic effects of acipimox treatment on glucose and lipid metabolism in patients with type 2 diabetes.
    Saloranta C, Groop L, Ekstrand A, Franssila-Kallunki A, Eriksson J, Taskinen MR.
    Diabet Med; 1993 Dec; 10(10):950-7. PubMed ID: 8306591
    [Abstract] [Full Text] [Related]

  • 2. Long-term effects of a sustained-release preparation of acipimox on dyslipidemia and glucose metabolism in non-insulin-dependent diabetes mellitus.
    Davoren PM, Kelly W, Gries FA, Hubinger A, Whately-Smith C, Alberti KG.
    Metabolism; 1998 Mar; 47(3):250-6. PubMed ID: 9500558
    [Abstract] [Full Text] [Related]

  • 3. The effect of an antilipolytic agent (acipimox) on the insulin resistance of lipid and glucose metabolism in hypertriglyceridaemic patients.
    Saloranta C, Groop L, Ekstrand A, Franssila-Kallunki A, Taskinen MR.
    Acta Diabetol; 1994 Apr; 31(1):6-13. PubMed ID: 8043900
    [Abstract] [Full Text] [Related]

  • 4. A double blind study of the effect of acipimox on serum lipids, blood glucose control and insulin action in non-obese patients with type 2 diabetes mellitus.
    Fulcher GR, Catalano C, Walker M, Farrer M, Thow J, Whately-Smith CR, Alberti KG.
    Diabet Med; 1992 Dec; 9(10):908-14. PubMed ID: 1478035
    [Abstract] [Full Text] [Related]

  • 5. Metabolic effects of suppression of nonesterified fatty acid levels with acipimox in obese NIDDM subjects.
    Fulcher GR, Walker M, Catalano C, Agius L, Alberti KG.
    Diabetes; 1992 Nov; 41(11):1400-8. PubMed ID: 1397716
    [Abstract] [Full Text] [Related]

  • 6. Metabolic consequences of sustained suppression of free fatty acids by acipimox in patients with NIDDM.
    Saloranta C, Taskinen MR, Widen E, Härkönen M, Melander A, Groop L.
    Diabetes; 1993 Nov; 42(11):1559-66. PubMed ID: 8405695
    [Abstract] [Full Text] [Related]

  • 7. Pronounced blood glucose-lowering effect of the antilipolytic drug acipimox in noninsulin-dependent diabetes mellitus patients during a 3-day intensified treatment period.
    Worm D, Henriksen JE, Vaag A, Thye-Rønn P, Melander A, Beck-Nielsen H.
    J Clin Endocrinol Metab; 1994 Mar; 78(3):717-21. PubMed ID: 8126147
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Improvement of lipoprotein lipid composition in type II diabetic patients with concomitant hyperlipoproteinemia by acipimox treatment. Results of a multicenter trial.
    Koev D, Zlateva S, Susic M, Babic D, Profozic V, Skrabalo Z, Langrová H, Cvrkalová AL, Rajecová E, Klimes I.
    Diabetes Care; 1993 Sep; 16(9):1285-90. PubMed ID: 8404433
    [Abstract] [Full Text] [Related]

  • 13. The effects of changes in plasma nonesterified fatty acid levels on oxidative metabolism during moderate exercise in patients with non-insulin-dependent diabetes mellitus.
    Akanji AO, Osifo E, Kirk M, Hockaday TD.
    Metabolism; 1993 Apr; 42(4):426-34. PubMed ID: 8487664
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effects of an acute decrease in non-esterified fatty acid levels on muscle glucose utilization and forearm indirect calorimetry in lean NIDDM patients.
    Piatti PM, Monti LD, Davis SN, Conti M, Brown MD, Pozza G, Alberti KG.
    Diabetologia; 1996 Jan; 39(1):103-12. PubMed ID: 8720610
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Peripheral and hepatic insulin sensitivity in non-insulin-dependent diabetes mellitus: effect of nonesterified fatty acids.
    Walker M, Agius L, Orskov H, Alberti KG.
    Metabolism; 1993 May; 42(5):601-8. PubMed ID: 8492715
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The role of plasma non-esterified fatty acids during exercise in type 2 diabetes mellitus.
    Berrish TS, Elliott C, Cooper BG, Reed JW, Orskov H, Alberti KG, Walker M.
    Diabet Med; 1993 Mar; 10(2):152-8. PubMed ID: 8458192
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.